News | Proton Therapy | September 02, 2022

The first of 396 patients has been enrolled into the PROTECT-trial with the aim of setting new standards for the clinical use of proton radiotherapy in esophageal cancer 

The first of 396 patients has been enrolled into the PROTECT-trial with the aim of setting new standards for the clinical use of proton radiotherapy in esophageal cancer

September 2, 2022 —  IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces that the PROTECT-trial consortium has enrolled the first patient in the PROTECT-trial investigating proton therapy in esophageal cancer.

The PROTECT (PROton versus photon Therapy for Esophageal Cancer – a Trimodality strategy) trial is a large-scale, multi-institutional, randomized controlled clinical trial, comparing the clinical outcomes of proton therapy and state-of-the-art photon radiotherapy for locally advanced esophageal cancer, with the goal of improving outcomes for this group of patients. The trial was developed by the European Particle Therapy Network (EPTN). IBA is one of two leading industry collaborators involved in the trial. 

A total of 396 patients will be included in the randomized study with completion expected by 2027. A key objective of the PROTECT-trial is to reduce treatment related side effects and improve quality of life for the patients suffering from esophageal cancer. In addition, an important aspect of the study is to improve patient selection for proton therapy by evaluating existing selection criteria and creating shared guidelines for reimbursement. 

The PROTECT-trial consortium is a private-public collaborative project that includes 12 proton therapy centers, 17 academic partners, and more than 30 clinical trial sites across eight countries. 

Dr. Karin Haustermans, Co-chief Investigator and Medical Director of the Proton Therapy Center ParTICLe at UZ Leuven, Belgium, commented: "The PROTECT study will gather data on the benefits of proton therapy from multiple centers across Europe, for the first time. This sets the direction for the future use of proton therapy and could provide meaningful evidence for the benefits of proton therapy, which is needed to expand its use and identify the patients that benefit the most from treatment with protons."

Olivier Legrain, Chief Executive Officer of IBA, added: "We are pleased to see the PROTECT-trial consortium reaching its first significant milestone of starting patient recruitment. At IBA we are truly passionate about the benefits proton therapy can provide patients living with cancer, including reducing the side effects of treatment as well as improving quality of life whilst they receive it. We are very proud to be involved with the consortium and look forward to seeing the results of this study which we hope will produce high-quality clinical evidence on the advantages of proton therapy." 

For more information: www.iba-worldwide.com 

Find more content on ASTRO22 


Related Content

News | PACS

February 22, 2024 — aycan, a recognized leader in medical imaging, announced that Enspectra Health used aycan’s PACS ...

Time February 22, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Treatment Planning

February 2, 2024 — RaySearch Laboratories announced that the number of radiotherapy centers that have chosen RayStation ...

Time February 02, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

It's a new year, and as another month comes to a close, ITN takes a look at the Top 10 most-read pieces of content from ...

Time February 01, 2024
arrow
News | Radiation Oncology

January 30, 2024 — The largest professional societies representing radiation oncology physicians in the United States ...

Time January 30, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time January 29, 2024
arrow
Subscribe Now